We are live on ! Find out more
VTGN icon

VistaGen Therapeutics

106 hedge funds and large institutions have $269M invested in VistaGen Therapeutics in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 38 increasing their positions, 29 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

104% more capital inflows, than outflows

Capital inflows: $25.3M | Capital outflows: $12.4M

31% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 29

2% more funds holding

Funds holding: 104 → 106 (+2)

1.05% more ownership

Funds ownership: 68.13% → 69.18% (+1%)

18% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 11

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

93% less call options, than puts

Call options by funds: $73K | Put options by funds: $1.04M

Holders
106
Holders Change
+2
Holders Change %
+1.92%
% of All Funds
1.63%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
9
Increased
38
Reduced
29
Closed
11
Calls
$73​K
Puts
$1.04​M
Net Calls
-⁠$966​K
Net Calls Change
-⁠$312​K

VTGN Hedge Fund Activity: Q4 2021 in Review

106 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q4 2021, worth a combined $269M — down 25% from $360M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of VTGN and 9 opened new positions — a net loss of 2 holders — while 29 trimmed existing stakes and 38 added.

The largest buyer was Commodore Capital, adding an estimated $7.25M. The largest seller was EAM Investors, exiting entirely with an estimated $2.31M sold.

  • 106 institutional investors held VistaGen Therapeutics (VTGN) as of Q4 2021, up from 104 in Q3 2021.
  • Funds reported $269M of VistaGen Therapeutics stock for Q4 2021, down 25% quarter-over-quarter.
  • 9 funds opened new VistaGen Therapeutics positions in Q4 2021 and 11 closed out, a net change of -2 holders.
  • The largest VistaGen Therapeutics buyer in Q4 2021 was Commodore Capital, an estimated $7.25M added.
  • The largest VistaGen Therapeutics seller in Q4 2021 was EAM Investors, an estimated $2.31M sold.

Based on aggregated 13F filings for Q4 2021.